Amethyst Healthcare and Stingray join forces to create Europe’s largest Independent Cancer Care platform
Amethyst Healthcare today announced the creation of Europe’s largest independent cancer care platform following its combination with Stingray Healthcare, a leading European oncology network headquartered in Lausanne, Switzerland. The transaction follows Fremman Capital’s acquisition of Stingray from Jacobs Capital.
The new group brings together two highly complementary organisations united by a shared mission to expand access to high-quality, patient-centred cancer care across Europe and be the partner of choice for cancer care professionals and institutions. Together, they will operate more than 30 treatment centres in eight countries, delivering around 35,000 radiotherapy treatments annually with over 60 state-of-the-art linear accelerators, making the combined group the largest independent cancer care provider in Europe.
Founded in 2010, Amethyst operates one of Europe’s most established networks of oncology and radiotherapy treatment centres across France, Poland, Romania, the UK, Italy, Portugal, and Austria. Stingray, founded in 2017 by Jacobs Capital and CEO Ralph Hefti, has developed a strong presence in France and Germany, Europe’s two largest radiotherapy markets, through its distinctive doctor partnership model and commitment to clinical excellence.
The merger will significantly strengthen the group’s footprint in Western and Central Europe, enhance its clinical expertise, and provide a robust foundation for continued investment in advanced treatment technologies, research, and innovation. Both Amethyst and Stingray will maintain their local identities while leveraging shared expertise and best practices to deliver world-class care.
Ralph Hefti, Founding CEO of Stingray and incoming CEO of the enlarged group, commented:
“This marks a pivotal moment for our teams and patients across Europe. By combining the complementary strengths of Stingray and Amethyst, we are creating a truly pan-European platform with the scale and capability to transform cancer care. Together, we are uniting outstanding clinicians, cutting-edge technology, and a shared vision to make high-quality oncology treatment more accessible to patients everywhere.”
Edward Chandler, Founding Partner at Fremman Capital added:
“This is a transformational moment for cancer care in Europe. By bringing together two highly complementary organisations, we are creating the scale, quality, and reach needed to improve access to state of the art oncology treatment across the continent. We look forward to supporting Ralph and his team in building Europe’s leading independent cancer care platform. ”
About Amethyst Healthcare
Founded in 2010, Amethyst Healthcare is the largest private provider of Radiotherapy services in Europe, delivering next generation (non-surgical) oncology treatment across the international Cancer Care market in Austria, France, Italy, Poland, Romania and the UK, operating 21 specialist centres, comprising 34 Linear Accelerators (Linacs) and two Gamma Knife Radiosurgery centers.
About Stingray Healthcare
Founded in 2017, Stingray Healthcare is an alliance of medical professionals, healthcare managers, and entrepreneurs dedicated to advancing cancer care, operating 10 radiotherapy and Gamma Knife centres in Germany and France. Through a distinctive doctor partnership model, Stingray supports established practices with financial resources and strategic expertise to deliver the highest quality of care to patients. Learn more at Stingray-healthcare.com
About Fremman Capital
Fremman is a pan-European, mid-market investment firm with offices in London, Madrid, Paris, Munich, Milan, and Luxembourg. Founded in 2020, Fremman partners with successful founders and management teams to transform businesses from local champions to multinational sustainable leaders. Learn more at fremman.com
For media inquiries, please contact: Sophie Ward, Amethyst Healthcare [email protected]
